THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
Abstract
Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective study, we discovered that circulating thrombospondin-2 (THBS2) could, in combination with CA19-9, better distinguish patients with PDAC versus...
Paper Details
Title
THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma
Published Date
Oct 26, 2021
Journal
Volume
12
Issue
22
Pages
2266 - 2272
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History